Recruiting Rheumatoid Arthritis Studies in Paris
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy....
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
Study J4B-MC-OKAA is a Phase 1/2, multi-center, open-label ascending dose, first-in-human study that will evaluate the safety and effect of intra-cisternal LY3884963 administration on progranulin prot...
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG. Trial details include: ...
Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG....
About Rheumatoid Arthritis Clinical Trials in Paris
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1.3 million Americans, where the immune system mistakenly attacks joint linings, causing painful swelling, bone erosion, and joint deformity. Early diagnosis and treatment are critical to prevent irreversible damage. Current standard treatments include methotrexate and other DMARDs, TNF inhibitors (etanercept, infliximab), IL-6 inhibitors (tocilizumab), T-cell costimulation modulators (abatacept), and JAK inhibitors (tofacitinib, baricitinib). Clinical trials are now exploring next-generation targeted therapies, dual-pathway inhibitors, and treatment strategies aimed at achieving sustained remission rather than just symptom control. Patients with inadequate response to conventional DMARDs or biologics are commonly eligible for enrollment.
There are currently 4 rheumatoid arthritis clinical trials recruiting participants in Paris, PARIS. These studies are seeking a combined 94 participants. Research is being sponsored by Minoryx Therapeutics, S.L., Prevail Therapeutics, argenx and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Rheumatoid Arthritis Clinical Trials in Paris — FAQ
Are there rheumatoid arthritis clinical trials in Paris?
Yes, there are 4 rheumatoid arthritis clinical trials currently recruiting in Paris, PARIS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Paris?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Paris research site will contact you about next steps.
Are clinical trials in Paris free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Paris studies also compensate for your time and travel.
What rheumatoid arthritis treatments are being tested?
The 4 active trials in Paris are testing new therapies including novel drugs, biologics, and treatment approaches for rheumatoid arthritis.
Data updated March 2, 2026 from ClinicalTrials.gov